1. Nassar, Amin H, Abou Alaiwi, Sarah, Baca, Sylvan C, Kwiatkowski, David J, Freedman, Matthew L. 2023. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma. In Nature communications, 14, 346. doi:10.1038/s41467-023-35833-5. https://pubmed.ncbi.nlm.nih.gov/36681680/
2. Otero-Albiol, D, Santos-Pereira, J M, Lucena-Cacace, A, Yoshida, Y, Carnero, A. 2024. Hypoxia-induced immortalization of primary cells depends on Tfcp2L1 expression. In Cell death & disease, 15, 177. doi:10.1038/s41419-024-06567-z. https://pubmed.ncbi.nlm.nih.gov/38418821/
3. Cardenas-Diaz, Fabian L, Liberti, Derek C, Leach, John P, Morley, Michael P, Morrisey, Edward E. 2023. Temporal and spatial staging of lung alveolar regeneration is determined by the grainyhead transcription factor Tfcp2l1. In Cell reports, 42, 112451. doi:10.1016/j.celrep.2023.112451. https://pubmed.ncbi.nlm.nih.gov/37119134/
4. Wang, Xiaohu, Wang, Xiaoxiao, Zhang, Shuyuan, Zhang, Xuewu, Ye, Shou-Dong. 2019. The transcription factor TFCP2L1 induces expression of distinct target genes and promotes self-renewal of mouse and human embryonic stem cells. In The Journal of biological chemistry, 294, 6007-6016. doi:10.1074/jbc.RA118.006341. https://pubmed.ncbi.nlm.nih.gov/30782842/
5. Zeng, C, Zhang, Y, Lin, C, Li, Y, Guan, H. 2024. TFCP2L1, a potential differentiation regulator, predicts favorable prognosis and dampens thyroid cancer progression. In Journal of endocrinological investigation, 47, 2953-2968. doi:10.1007/s40618-024-02392-5. https://pubmed.ncbi.nlm.nih.gov/38753296/
6. Qiu, Dongbo, Wang, Tiantian, Xiong, Yi, Zhang, Qi, Jia, Changchang. 2024. TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma. In Oncogenesis, 13, 33. doi:10.1038/s41389-024-00534-1. https://pubmed.ncbi.nlm.nih.gov/39266516/
智鼠故事 
